Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Ramm Pharma ( (TSE:RAMM) ) is now available.
RAMM Pharma Corp. has received minority shareholder approval for a proposed investment transaction with The Global South S.A.S., involving a US$5 million investment for a 10% equity interest. The transaction includes a call option for RAMM to acquire an additional 15% equity interest, contingent on securing necessary funds and regulatory approvals, which could enhance RAMM’s market positioning and growth potential.
Spark’s Take on TSE:RAMM Stock
According to Spark, TipRanks’ AI Analyst, TSE:RAMM is a Neutral.
Ramm Pharma’s overall stock score is primarily impacted by its poor financial performance, characterized by significant operational losses and cash flow issues. Technical analysis provides some positive signals, but the overbought conditions and negative valuation metrics further weigh down the score.
To see Spark’s full report on TSE:RAMM stock, click here.
More about Ramm Pharma
RAMM Pharma Corp. is engaged in cannabinoid pharmacology and product formulation for cannabis-based pharmaceuticals and hemp-based products. The company operates internationally with production and sales platforms in Europe, including large extraction and processing facilities in Italy and Poland. Its subsidiaries include Canapar Corp., HemPoland Sp. Z o.o., Medic Plast SA, Yurelan SA, and RAMM Pharma Holdings Corp.
Average Trading Volume: 211,640
Technical Sentiment Signal: Buy
Current Market Cap: C$8.95M
Find detailed analytics on RAMM stock on TipRanks’ Stock Analysis page.